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ABSTRACT

Breast cancer is the most commonly diagnosed cancer among women in the
United States, affecting about 12 percent of women nationally (Ma and Jemal, 2013). The
American Cancer Society estimates that 246,600 new cases of invasive breast cancer will
be diagnosed in women in 2016 (American Cancer Society, 2016 b). Breast cancer
accounts for almost 30% of new cancer diagnoses and is one of the leading causes of
cancer related deaths among women in developed countries. In addition, breast cancer is
becoming a worldwide problem with incidence and mortality rates increasing steadily
over the past 20 years in developing countries (Ma and Jemal, 2013).
Current treatment options for breast cancer include surgery, chemotherapy, and
radiation; however, there are many negative side effects associated with these treatments,
and these treatments are not always suitable for every patient. In addition, there is a risk
of local breast cancer recurrence, particularly in patients who undergo a lumpectomy. Up
to 20% of breast cancer patients experience recurrence, and of these recurrences, around
70% are defined as local (Zimmerman and Mehr, 2014). Therefore, there is a need for the
development of a therapeutic agent specifically designed to target the surgical site and
minimize the risk of locally recurrent breast cancer.
The overall goal of this research was to develop an injectable soft tissue
regeneration matrix for the prevention of local HER2+ breast cancer recurrence. Collagen
type I beads were crosslinked with tannic acid (TA) to form the basis for the injectable
therapy. The collagen beads were seeded with human adipocytes. The adipocytes attach
and grow on the collagen beads, thus remodeling the beads and releasing the tannic acid
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to the surrounding environment. The tannic acid acts as an anticancer therapeutic agent
by inducing apoptosis in HER2+ breast cancer cells via caspase pathways.
In order to prove the viability of this therapeutic option, several studies were
conducted. LIVE/DEAD assays were used to prove successful seeding of the human
adipocytes onto the collagen beads. Cell viability studies were conducted to assess the
effect of tannic acid on human adipocytes and HER2+ breast cancer cells. In addition, the
Folin-Ciocalteu assay was used to analyze the release profile of tannic acid. RNA was
isolated from both the human adipocytes and HER2+ breast cancer cells, and Real TimePCR was conducted to determine the activated pathways involved in cell apoptosis as a
result of exposure to tannic acid. Western blotting was used to identify expression of
caspases from proteins isolated from the HER2+ breast cancer cell line and normal human
breast epithelial cell line.
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CHAPTER ONE
INTRODUCTION AND BACKGROUND
1.1 Project Overview
The current standard of care for breast cancer treatment includes surgery in which
the cancerous lump and the surrounding tissue are removed, leaving a void as shown in
Figure 1.1. The overall goal of this project is to develop an injectable tannic acid
crosslinked collagen type I bead matrix to prevent local breast cancer recurrence. The
technology shown in Figure 1.2 incorporates the patient’s adipocytes that are seeded onto
the tannic acid crosslinked collagen type I beads. As the adipocytes attach and grow on
the beads, they cause remodeling of the collagen and release of the tannic acid which then
interacts with and kills any residual cancer cells in the tissue surrounding the void.

Figure 1.1: Lumpectomy Procedure (Keck School of Medicine of USC, 2016)
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Figure 1.2: TA Crosslinked Collagen Type I Seeded with Adipocytes

1.2 Breast Anatomy
The female breast is composed primarily of adipose tissue and glandular tissue,
extending from the clavicle to the center of the sternum or from the second rib to the
sixth rib (Zhu and Nelson, 2013). Therefore, the breasts cover the majority of the chest
and chest walls. The adult female breast contains 12 to 20 lobes, which are made up of 20
to 40 lobules (Zhu and Nelson, 2013). The breast lobules are formed by groups of
secretory units, known as alveoli, which are lined by cuboidal, milk-secreting cells and
encircled by myoepithelial cells (Barcellos-Hoff et al., 1989). It is within the alveoli that
milk is produced in response to hormonal signals (McKinley and O’Loughlin, 2012).
Small ducts which drain milk from the alveoli and lobules join and form 10 to 20 large
ducts known as lactiferous ducts (McKinley and O’Loughlin, 2012). Each breast lobe is
drained by a single lactiferous duct. Close to the nipple, the lumen of each lactiferous
duct expands, forming a lactiferous sinus in which the milk is stored prior to lactation via
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the nipple (McKinley and O’Loughlin, 2012). The breast structure is shown in Figures
1.3 and 1.4.
The functional components of the breast are surrounded by adipose tissue. Fibrous
connective tissue or fascia, suspensory ligaments known as Cooper’s ligaments, lymph
vessels, lymph nodes, and blood vessels are found within this adipose tissue (O’Connell
and Rusby, 2015). Superficial and deep fascia, along with the Cooper’s suspensory
ligaments, help provide structure, support, and attachment of the breast to the chest
(Bland and Copeland, 1998). Lymph vessels carry lymph, a mixture of white blood cells,
proteins, fats, and interstitial fluid, to lymph nodes. The lymph nodes are responsible for
filtering the lymph fluid to remove any foreign substances or abnormal cells, which is an
important component of the immune system (Bland and Copeland, 1998). Lastly, blood
vessels provide the breast tissue with necessary oxygen and nutrients, while removing
waste.
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Figure 1.3: Anterior view of breast structure (McKinley and O’Louglin, 2012)
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Figure 1.4: Sagittal view of breast structure (McKinley and O’Loughlin, 2012)

1.3 Breast Development
Until puberty, the structure of the breast is identical in females and males (Chau et
al., 2016). At the onset of puberty in females, thelarche, or secondary breast
development, begins (Nakamoto, 2000). In response to female sex hormones and growth
hormone, breasts sprout, grow, and develop, changing in size and volume (Javed and
Lteif, 2013). About two years after the onset of puberty, females undergo further breast
development. The female sex hormone estrogen and growth hormone promote the growth
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and development of the fat, glandular, and suspensory tissue structures of the adult
female breast (Javed and Lteif, 2013). This development typically continues for about
four years until the final breast size, volume, and density is established. It is important to
note that breast size and volume does fluctuate in response to hormonal changes during
thelarche, menstruation, pregnancy, lactation, and menopause. During pregnancy,
estrogen, progesterone, and prolactin cause the growth of ducts and glandular tissue
(Javed and Lteif, 2013). In addition, the water, electrolyte, and fat content of the breast as
well as its vascularity increase during pregnancy leading to an increase in overall breast
volume (Javed and Lteif, 2013). At the onset of menopause, the body stops producing the
female sex hormones estrogen and progesterone (Santoro and Randolph Jr., 2011). This
loss of hormones results in shrinkage of lobules and glandular tissue (Kalogerakos et al.,
2014). In addition, breast density decreases as a result of menopause due to this tissue
atrophy.

1.4 Breast Cancer Statistics
Breast cancer is the most commonly diagnosed cancer among women in the
United States and affects about 12 percent of women nationally (Ma and Jemal, 2013).
The American Cancer Society estimates that 246,660 new cases of invasive breast cancer
will be diagnosed in women in 2016 (American Cancer Society, 2016 b). Breast cancer
accounts for almost 30% of new cancer diagnoses and is one of the leading causes of
cancer deaths among women in developed countries. In addition, breast cancer is
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becoming a worldwide problem with incidence and mortality rates increasing steadily
over the past 20 years in developing countries (Ma and Jemal, 2013).

1.5 Breast Cancer Classification
1.5.1 Stages of Breast Cancer
After the initial breast cancer diagnosis, the breast cancer is staged based on
tumor size and invasiveness, status of lymph nodes, and metastasis (National Breast
Cancer Foundation, Inc. a, 2015).
1.5.1.1 Stage 0
Stage 0 describes non-invasive breast cancers in which the abnormal, cancerous
cells have not spread beyond their place of origin. Stage 0 breast cancer includes ductal
carcinoma in situ, lobular carcinoma in situ, and Paget disease of the nipple (National
Breast Cancer Foundation, Inc. b, 2015).
1.5.1.2 Stage I
Stage I is used to describe invasive breast cancers in which the cancerous cells
have begun invading the surrounding breast tissue. Stage IA includes tumors measuring
up to 2 cm and no lymph node involvement. Stage IB describes small groups of cancer
cells between 0.2 mm and 2 mm in the lymph nodes instead of a breast tumor or a breast
tumor measuring up to 2 cm and small groups of cancer cells between 0.2 mm and 2 mm
in the lymph nodes (National Breast Cancer Foundation, Inc. b, 2015).
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1.5.1.3 Stage II
Stage II also describes invasive breast cancer and is subdivided into Stages IIA
and IIB. Stage IIA includes tumors larger than 2 mm in 1 to 3 surrounding lymph nodes
instead of a breast tumor, breast tumors measuring more than 2 cm that have spread to
axillary lymph nodes, and breast tumors between 2 cm and 5 cm that have not spread to
the lymph nodes. Stage IIB includes breast tumors between 2 cm and 5 cm and small
groups of cancer cells between 0.2 mm and 2 mm in the surrounding lymph nodes, breast
tumors between 2 cm and 5 cm that has spread to 1 to 3 surrounding lymph nodes, and
breast tumors larger than 5 cm that have not spread to the lymph nodes (National Breast
Cancer Foundation, Inc. c, 2015).
1.5.1.4 Stage III
Stage III describes invasive breast cancer and is subdivided into Stages IIIA, IIIB,
and IIIC. Stage IIIA includes tumors found in 4 to 9 surrounding lymph nodes instead of
a breast tumor, breast tumors larger than 5 cm and small groups of cancer cells between
0.2 mm and 2 mm in the surrounding lymph nodes, and breast tumors larger than 5 cm
that have spread to 1 to 3 surrounding lymph nodes. Stage IIIB describes breast tumors of
any size that have spread to the chest wall or skin and up to 9 surrounding lymph nodes.
Stage IIIB includes inflammatory breast cancer. Stage IIIC describes breast tumors of any
size and/or cancer in 10 or more surrounding lymph nodes (National Breast Cancer
Foundation, Inc. d, 2015).
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1.5.1.5 Stage IV
Lastly, Stage IV describes metastatic breast cancer that has spread outside of the
breast tissue and surrounding lymph nodes into other organs of the body (National Breast
Cancer Foundation, Inc. e, 2015)
1.5.2 Hormone Receptor and HER2 Classification
In addition to staging, breast cancer is often classified based on the presence of
hormone receptors and the status of human epidermal growth factor receptor-2 (HER2)
protein. After pathological examination, the cancer is assigned a classification of
hormone receptor-positive or receptor-negative, such as estrogen receptor-positive (ER+)
and progesterone receptor-positive (PR+), HER2-positive (HER2+), triple positive, or
triple negative. Around 70% of primary breast cancers are classified as hormone
receptor-positive/HER2-, 10% hormone receptor-positive/HER2+, 12% triple negative,
and 5% hormone receptor-negative/HER2+ (Howlader et al., 2014). These classifications
are important in determining the most appropriate treatment options.

1.6 Clinical Treatment Options
Current

clinical

treatment

options for breast cancer include
surgery,

radiation

Stage

5-year Survival Rate (%)

0

100

I

100

II

93

III

72

IV

22

therapy,

chemotherapy, hormonal therapy, and
targeted therapy. Typically patients are
treated with a combination of these

Table 1.1: Breast Cancer Survival Rates, by
Stage (American Cancer Society, 2016 a)
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therapies based on overall health, location and type of cancer, and disease spreading
(Peart, 2015). According to the American Cancer Society’s 5-yr survival rate data, these
treatment options have proven to be successful, particularly in treating earlier stages of
breast cancer (see Table 1.1) (American Cancer Society, 2016 a).
In spite of the high success rates for these treatment options, there remain many
disadvantages associated with each. Surgery is extremely effective at removing a single
tumor; however, it is associated with long recovery times, risks of excessive bleeding and
infection, as well as psychological trauma (Arroyo and López, 2011). Radiation locally
targets the tumor using high energy x-rays but is associated with swelling fatigue, and
nerve damage (American Cancer Society, 2016 e). Chemotherapy is a systemic treatment
incapable of specifically targeting the tumor, thus damages and kills healthy cells. It is
also associated with many negative side effects including, hair loss, nausea, increased
risk of infection due to low white blood cell counts, heart damage, and fatigue (American
Cancer Society, 2016 c). Hormonal therapy is not capable of killing the cancerous cells of
the tumor; it simply slows the progression of the disease (American Cancer Society, 2016
d). In addition, hormonal therapy is obviously not suitable for hormone receptor-negative
breast cancer cell types and can lead to mood swings, blood clots, and increased risk of
myocardial infarction (American Cancer Society, 2016 d). Lastly, side effects of targeted
therapies include severe diarrhea, heart damage, and congestive heart failure (American
Cancer Society, 2016 f). Targeted therapies are often coupled with other treatment
options such as chemotherapy and/or hormonal therapy which are also associated with
heart damage; thus, the potential heart damage is compounded putting the patient at a
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higher risk (Bodai and Tuso, 2015). In addition to these side effects, targeted therapies
are not suitable for pregnant women because they can result in severe damage to the fetus
(Basta et al., 2015). All current treatment options for breast cancer patients have
significant limitations and side effects; therefore, there is a need for a novel therapeutic
agent against breast cancer.

1.7 Polyphenols
Polyphenols are a structural class of chemicals characterized by multiple hydroxyl
groups attached to an aromatic ring (Vermerris and Nicholson, 2006). Polyphenols are
classified as either flavonoids or non-flavonoids based on their chemical structure,
biological function, and source (Mocanu et al., 2015). The flavonoid group includes
flavonols, flavones, flavanols, anthocyanins, flavanones, and isoflavones. The nonflavonoid group is comprised of phenolic acids, stilbenes, lignans, and tannins (Pandey
and Rizvi, 2009). Polyphenols are of great scientific interest due to their abundance with
over 8000 identified species and their demonstrated health benefits.
1.7.1 Tannins
One polyphenolic subset of interest is the tannin group. Tannins are water-soluble
polyphenolic compounds and are classified as either hydrolysable or condensed (Petridis,
2011). Hydrolyzable tannins have a polyhydric alcohol core and hydroxyl groups that
have been partially or wholly esterified by gallic acid or hexahydroxydiphenic acid.
Condensed tannins are generally products of polymerized flavan-3-ols and flavan-3,4diols (Chung et al., 1998). The various tannin classifications are shown in Figure 1.5.
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Tannins are found in a wide variety of plants including grains, fruits, nuts, and legumes,
and also in drinks such as wine, green tea, and coffee (Carlsen et al., 2010; Oliveira et al.,
2014; Mojzer et al., 2016). In addition to availability, studies have also shown an inverse
relationship between high tannin consumption and cancer development; therefore, tannins
are an ideal candidate as a novel, therapeutic anticancer agent and have been widely
studied (Stich and Rosin, 1984).

Figure 1.5: Tannin Classifications (Khanbabaee and van Ree, 2001)
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1.8 Anticancer Properties and Mechanisms of Tannins against Breast Cancer
1.8.1 Tannin Effects on ER+ Breast Cancer
ER+ breast cancer has been shown to be susceptible to the anti-carcinogenic
effects of tannins in numerous studies (Babili et al., 2010; Booth et al., 2013; Fujita et al.,
2001; Bawadi et al., 2005; Losso et al., 2004; Zhang et al., 2008; Wakil, 1989; Kuhajda,
2000; Shirode et al., 2013). Tannins such as ellagic acid and gallic acid do not possess
estrogenic activity (Zand et al., 2000); therefore, recent studies have focused on other
mechanisms of interference.
We (Booth et al., 2013) demonstrated that tannic acid (TA) caused a change in
morphology of MCF7 ER+ breast cancer cells from spindle shaped cells to round cells.
TA induced significant apoptosis in the ER+ breast cancer cells within 24 hours of
exposure, indicating their high sensitivity to the apoptotic effects of TA. In addition to
demonstrating the decrease in cell viability and increase in apoptotic activity as a result of
TA exposure, we determined the mechanism involved in apoptosis initiation in ER+
breast cancer cells. Apoptosis is induced via activation of the caspases 3/7 and 9. We
further postulated that the high sensitivity of MCF7 ER+ breast cancer cells to TA
treatment is related to the lack of caspase 3 expression by the MCF7 cells (Booth et al.,
2013). Caspase 3 can act as a negative feedback regulator of caspase 9 since it is
downstream of caspase 9 (Fujita et al., 2001).
Bawadi et al (Bawadi et al., 2005; Losso et al., 2004) treated ER+ breast cancer
cells with water-soluble condensed tannins derived from black beans. Through
microscopy, it was shown that tannin treatment disrupts cellular integrity and that cell
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death occurred via apoptosis. The tannin cytotoxicity was assessed with a ViaLight HS
luciferin and luciferase-based assay using ATP bioluminescence as a cell viability and
proliferative ability marker. ATP levels steadily decreased with increasing tannin
concentrations for 24 hours indicating decreased cell proliferation and migration
activities. The condensed tannins were shown to decrease the activities of
metalloproteinase-2 (MMP-2) and MMP-9 to less than 50% of their activity compared to
the control cancer cells. The researchers hypothesized that this effect could be associated
with the metal chelating properties of tannins, allowing them to bind zinc thus making it
unavailable for MMP activity. Condensed tannin treatment reduced the levels of vascular
endothelial growth factor (VEGF) in the media. MMPs and VEGF are angiogenic factors
necessary for new blood vessel formation; therefore, inhibiting their activity inhibits
cancer cell proliferation, migration, progression, and metastasis.
Another study showed tannin induction of apoptosis via inhibition of fatty acid
synthase (FAS) (Zhang et al., 2008). FAS is an enzyme involved in de novo synthesis of
long chain fatty acids in vivo and is highly expressed in human cancers such as breast
cancer (Wakil, 1989; Kuhajda, 2000). Therefore, inhibition of FAS can directly lead to
apoptosis, making it an important therapeutic target for cancer treatment. After treatment
with condensed tannins derived from the catechu plant, an MTT assay for cell viability
was conducted to confirm growth inhibition of ER+ breast cancer cells in a dosedependent manner. It was also shown that the condensed tannins blocked most of the
enzymatic activity of FAS by inhibiting the β-ketoacyl reductase domain of FAS. This
inhibition was competitive to NADPH; therefore, it was hypothesized that the tannin
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reaction site is the NADPH loading site in the β-ketoacyl reductase domain of FAS. It is
also likely that condensed tannins react on the acyl transferase domain of FAS (Zhang et
al., 2008).
In order to decipher the mechanisms of action of hydrolysable tannins found in
pomegranate extract, Shirode et al (Shirode et al., 2013) conducted several studies using
ER+ breast cancer cells. The group confirmed previous results that tannins inhibit cell
growth by inducing cell cycle arrest in G2/M followed by apoptosis induction. DNA
microarray analysis showed that tannins from pomegranate extract downregulated genes
involved in mitosis, chromosome organization, RNA processing, DNA replication, and
DNA repair. Tannins also upregulated genes associated with regulation of apoptosis and
cell proliferation. DNA microarray and quantitative RT-PCR showed downregulation of
genes involved in DNA double strand break repair by homologous recombination,
including BRCA1, BRCA2, BRCC3, RAD50, RAD51, MRE11, and NBS1. In addition,
the levels of predicted microRNAs of homologous recombination genes increased
indicating regulation of miRNAs involved in DNA repair by tannins. Tannin treatment
increased the frequency of DNA double strand breaks, which is attributed to the
downregulation of homologous repair that causes cells to become more sensitive to DNA
double strand breaks, growth inhibition, and apoptosis.
1.8.2 Tannin Effects on HER2+ Breast Cancer
Tannins have proven to be cytotoxic to HER2+ and trastuzumab-resistant HER2+
breast cancer cells in a dose-dependent manner (Moongkarndi et al., 2004; Sonoda et al.,
2006; Signoretti et al., 2002; Huang et al., 2011; Banerjee et al., 2012; Eddy et al., 2007);
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therefore, the mechanism of action of tannins has been widely studied in HER2+ breast
cancer cells.
Tannins derived from the pericarps of garcinia mangostana were shown to have
antiproliferative and antioxidative effects on HER2+ breast cancer cells (Moongkarndi et
al., 2004). MTT reduction assays confirmed the antiproliferative effects after 48 hours of
exposure to mangostana-derived tannins, and showed a concentration-dependent decrease
in percent cell viability. Morphological analysis using Hoechst33342 and propidium
iodide (PI) staining revealed nuclear shrinking, DNA condensation, and DNA
fragmentation after 48 hours of tannin treatment. Phase contrast microscopy showed
cytoplasmic membrane shrinkage, loss of contact with neighboring cells, membrane
blebbing, and apoptotic bodies. DNA ladder patterns on agarose gel electrophoresis
exhibited oligonucleosomal DNA fragments from cells after tannin treatment. From the
results of the morphological analysis and agarose gel electrophoresis, it was concluded
that the tannins from the garcinia mangostana extract induced apoptosis in the HER2+
breast cancer cells. High dose treatments resulted in increased reactive oxygen species
(ROS) levels at 48 hours after treatment, followed by a decrease in ROS levels at 72
hours. It was hypothesized that the tannins induce apoptosis, at least in part, via high
ROS levels. These ROS levels then decrease over time because only cell debris remains.
In many different human cancers, including breast cancer, overexpression of the
F-box protein S-phase kinase-associated protein 2 (Skp2) is observed (Sonoda et al.,
2006; Signoretti et al., 2002). Skp2 plays a large role in the progression of breast cancer;
therefore, numerous studies have been performed to evaluate different chemopreventative
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agents in the downregulation of Skp2. One of these agents is 1,2,3,4,6-Penta-O-galloyl-βD-glucose, a precursor of gallotannins and ellagitannins, which is also referred to as 5gg.
Growth of HER2+ breast cancer cells was inhibited by 5gg in a dose and time-dependent
manner (Huang et al., 2011). In addition, through flow cytometry it was shown that 5gg
results in cell cycle arrest in the G1 phase, inhibiting cell growth. Skp2 is associated with
the S-phase promoting kinase cyclin A-cyclin-dependent kinase 2 (Cdk2) and plays an
important role in cell cycle progression regulation. Skp2 levels decrease when cells exit
the cell cycle and increase when cell re-enter the cell cycle. Skp 2 targets p27 for
degradation, thus acting as an oncogene. 5gg treatment causes Skp2 downregulation,
which contributes to the induction of cell cycle arrest in HER2+ breast cancer cells.
Pomegranate extract containing hydrolysable tannins reduced growth and tumor
volume of HER2+ breast cancer cells (Banerjee et al., 2012). Caspase-3 was activated,
indicating apoptosis was induced via caspase-mediated pathways. Treatment with
pomegranate extract decreased mRNA and protein levels of Sp transcription factors Sp1,
Sp3, and Sp4. Sp regulated genes cyclin D1, bcl2, VEGF, VEGFR-1, and NF-κB were
also decreased. These genes are involved in cell proliferation, angiogenesis, and
inflammation.
Epigallocatechin-3-gallate (EGCG), a condensed tannin isolated from green tea
leaves, treatment results in a dose-dependent decrease in ATP production in HER2+
resistant cancer cells, resulting in decreased cellular growth and proliferation (Eddy et al.,
2007). EGCG treatment caused a decrease in cell number after 96 hours. Through nuclear
morphology studies and Hoechst 33258 staining, DNA fragmentation and dispersal in the
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cytoplasm and loss of nuclear integrity were observed after high dose EGCG treatments,
indicating that EGCG induces apoptosis. EGCG treatment reduced Akt signaling in
trastuzumab-resistant HER2+ breast cancer cells in a dose-dependent manner and
increased nuclear expression of FOXO3a and its growth regulatory target gene p27. A
lack of p27 expression is associated with trastuzumab resistance, whereas induction of
p27 indicates trastuzumab sensitivity; therefore, the expression of p27 after EGCG
treatment indicates decreased resistance of the HER2+ breast cancer cells.
1.8.3 Tannin Effects on Triple Negative Breast Cancer
The effects of tannic acid and other chemopreventative agents have been of
interest and the subject of many different studies using triple negative breast cancer cell
lines. Triple negative breast cancer cells do not respond to normal hormonal therapies,
such as tamoxifen and aromatase inhibitors, and therefore different agents and therapies
have been studied.
Tannic acid has been investigated in order to determine its effects on breast
cancer cells. We published results where we (Booth et al., 2013) performed a study using
collage type-1 beads cross-linked with tannic acid in order to further understand the
effects of the tannic acid on different types of breast cancer cell lines. Though the effects
were less significant on the triple negative breast cancer cells compared to other types of
breast cancer, there was still a change in the morphology of the triple negative cells. In
addition, the proliferation rate of the treated cells was lower than that of untreated cells.
Tannic acid was shown to induce a significant level of apoptosis in the triple negative
cells that were treated as opposed to those that were not. The effect on caspase activation
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was also investigated. Once again, though the effects were not as dramatic as other types
of breast cancers, it was shown that caspases 9 and 3/7 were elevated once exposed to
tannic acid. All of the effects of tannic acid on the triple negative cell line were shown to
be both dose- and time-dependent.
Doxorubicin (DXR) is an anthracycline antibiotic that is effective in treating a
variety of solid tumors, including breast tumors. However, due to concerns about
toxicities, including cardiotoxicity, it has had limited use. A study by Tikoo et al (Tikoo
et al., 2010) showed that tannic acid, when combined with DXR, was able to reduce
cardiotoxicity of DXR while promoting the anti-cancer properties of DXR against the
triple negative cell line MDA-MB-231. In this study tumors were chemically induced in
rats with dimethylbenz[a] anthracene (DMBA) then treated with combinations of DXR
and tannic acid. DXR reduced the volume of the tumor as compared untreated tumors.
DXR enhanced the expression of the tumor suppressor gene p53, which led to an
inhibition of tumor growth. The addition of tannic acid was more effective than DXR
alone in elevating the expression of p53, resulting in inhibition of tumor growth. Tannic
acid gave protection against DXR-induced myocardial damage by preventing
cytoplasmic vacuolization.
Huang et al (Huang et al., 2011) determined the effects of 5gg on the cell cycle in
triple negative breast cancer cells that were overexpressing Skp2. The group found that
60% of the treated cells were in the G1 phase, as opposed to only 40% among the control
cells. After 48 hours of 5gg treatment, all triple negative breast cancer cells were arrested
in the G1 phase. These results indicated that 5gg halted the cell cycle of triple negative
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breast cancer cells. 5gg was able to modulate the expression of cell cycle regulatory
proteins, which then induced the arrest of the cell cycle. This effect was both time- and
dose-dependent.
Several studies have shown the ability of polyphenolics from pomegranate
(Punica granatum L.) to inhibit cancer cell proliferation and to induce apoptosis, promote
cell cycle arrest, and decrease inflammation. There is evidence that suggests this is in part
due to their role in decreasing specificity protein (Sp) factors. Banerjee et al extracted
mRNA for gene expression analysis from triple negative breast cancer cells treated with
pomegranate extract (Pg) after 24 hours and determined there was a concentrationdependent decrease in cell-viability after being treated with Pg (Banerjee et al., 2012).
There were not any significant effects on cytotoxicity in cells that were not treated under
the same conditions. The cytotoxicity induced by Pg was accompanied by activation of a
primary apoptosis-executing enzyme, caspase-3. Pg inhibited the proliferation of cancer
cells while inducing apoptosis.
Kim et al (Kim et al., 2002) studied three pomegranate components: polyphenolrich fractions from fermented juice, aqueous pericarp extracts, and cold-pressed or
supercritical CO2-extracted seed oil of pomegranates. The effects of these three
components on human triple negative breast cancer cells were investigated in vitro. The
polyphenols inhibited the proliferation of triple negative breast cancer cells in a dosedependent manner. Although the effects were not as profound as those found in other
types of breast cancer, it can be inferred that polyphenols from pomegranates play a role
in inhibiting the proliferation of triple negative breast cancer cells. All three components
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from which the polyphenols were extracted had an inhibitory effect on the proliferation
of the triple negative breast cancer cells.
In recent years, green tea extract has been studied in order to determine the
mechanisms of its anti-cancer effects. EGCG, a principal component of green tea, has
been shown to aid in both the prevention and the treatment of cancer by inhibiting
angiogenesis and tumor invasion, which are required for tumor growth and progression
(Khan and Mukhtar, 2010). One study showed suppressed growth and proliferation of
triple negative breast cancer cells as a result of EGCG treatment (Braicu et al., 2013). Li
et al (Li et al., 2014) reviewed the known effects of green tea extract on different breast
cancer cell lines. The findings suggest that the green tea extract containing EGCG is
capable of inducing cell cycle arrest and apoptosis in many different types of breast
cancer cell lines, including the MDA-MB-231 and MDA-MB-468 triple negative breast
cancer cells.
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CHAPTER TWO
MATERIALS AND METHODS
2.1 Collagen Bead Preparation
All storage/media bottles were autoclaved prior to use. All procedures were
conducted under sterile conditions in a biological safety cabinet (Labconco; Kansas City,
MO).
A 1.4% (mass/volume) alginate solution was prepared by adding 0.28 g of
alginate acid sodium salt from brown algae (Sigma Aldrich; St. Louis, MO) to 20 mL of
deionized water filtered using a milliQ system (millipore Direct 8; Darmstadt, Germany).
The solution was covered with Parafilm (Sigma Aldrich; St. Louis, MO) and then mixed
using a stir bar (VWR; Radnor, PA) on a stirrer/hot plate (Corning; Corning, NY) on
setting 2 (30 oC) until the alginate had dissolved. The alginate solution was then sterile
filtered under vacuum overnight using a 150 mL bottle top filter (Corning; Corning, NY)
and a 250 mL storage/media bottle (VWR; Radnor, PA).
Next, a 1.5% (mass/volume) CaCl2 solution was prepared by adding 3 g of
calcium chloride dihydrate (Fisher Scientific; Fair Lawn, NJ) to 200 mL of deionized
water filtered using a milliQ system (millipore Direct 8; Darmstadt, Germany). The
solution was mixed using a stir bar (VWR; Radnor, PA) on a stirrer/hot plate (Corning;
Corning, NY) at room temperature until dissolved. The CaCl2 solution was then sterile
filtered under vacuum using a 1000 mL bottle top filter (Corning; Corning, NY) and a
500 mL Pyrex storage/media bottle (Fisher Scientific; Fair Lawn, NJ).
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A 12 mL collagen solution was prepared on ice using a modified version of
Vernon and coworkers method (Vernon et al., 2005). First, 0.444 mL of 10X Dulbecco’s
Phosphate Buffered Saline (10X PBS) (Sigma Aldrich; St. Louis, MO) were added to 4
mL of purified bovine collagen solution (PureCol) (Advanced BioMatrix; San Diego,
CA). Then, 1.2 mL of fetal bovine serum (FBS) (Corning; Manassas, VA) were added to
the solution. Next, 6.356 mL of Dulbecco’s Modified Eagle Medium (DMEM) (ATCC;
Manassas, VA) were added to the solution. Lastly, 40 μL of 1 N NaOH (Sigma Aldrich;
St. Louis, MO) to the solution in order to neutralize the pH. This neutralization was
characterized by a color change from clear in color to pink in color, which is attributed to
the phenol red present in the DMEM.
The collagen solution and the 1.4% alginate solution were allowed to sit on ice for
30 minutes to ensure better flow. After chilling, the 1.4% alginate solution was added to
the collagen in a ratio of 40:60. Specifically, 8 mL of 1.4% alginate solution were added
to the 12 mL of prepared collagen solution.
Components for the bead generator including the glassware dish, petri dish,
electrostatic probe, silicone tubing (5/32” outer diameter and 3/32” inner diameter),
nozzle, and stir bar were autoclaved for 40 minutes at 121 oC in a large autoclave bag.
The Var V1 bead generator (Nisco; Zurich, Switzerland), KDS100 syringe pump (KD
Scientific; Holliston, MA), were sterilized using 70% ethanol (EthOH) and Kimwipes
(Kimberly-Clark; Roswell, GA).
The petri dish was place on the stage of the bead generator. The glassware dish
was then placed within the petri dish, and a stir bar was placed in the glassware dish. The
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electrostatic probe was then inserted into its holder and tightened using the screw. The
1.5% CaCl2 solution was poured into the glassware dish until it just overflowed into the
petri dish underneath. The probe was then lowered into position so that the tip of the
probe was immersed in the CaCl2 solution and tightened with the screw. The bead
generator and the agitator were then turned on so that the stir bar was rotating. The nozzle
was screwed into the luer lock of the silicone tubing and secured in the holder using the
screw. The silicone tubing was then fed through the notch at the top of the bead
generator, and the doors to the bead generator were closed. A 20 mL Luer-Lok syringe
(BD; Franklin Lakes, NJ) with a 16G 1 1/2 needle (BD; Franklin Lakes, NJ) was used to
load the 20 mL of 40:60 alginate: collagen solution, taking care to avoid bubble
formation. The syringe was then inverted and any air was forced out of the needle tip.
The needle was then removed, and the silicone tubing was attached to the luer-lock of the
syringe. The plunger of the syringe was then used to pump to alginate/collagen solution
through the tubing until the solution reached the nozzle. The syringe was then placed in
the syringe pump. The pump settings were adjusted to Volume: 20 mL, Rate: 10 mL/h,
Dia: 15, and then the run was started. The voltage of the bead generator was turned on
and set to 5.5 V. The bead generator was allowed to run until all of the alginate/collagen
solution had flown through the nozzle. The bead generator setup is shown in Figures 2.1
and 2.2.
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Figure 2.1: Electrostatic Bead Generator Setup
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Figure 2.2: Electrostatic Bead Generator Components
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Next, tannic acid cross-linking solutions were made. A 10.0% (mass/volume) TA
solution was made by adding 111 mL of deionized water filtered using a milliQ system
(millipore Direct 8; Darmstadt, Germany) to 11.1 g of tannic acid (Sigma Aldrich; St.
Louis, MO). The solution was mixed using a stir bar (VWR; Radnor, PA) on a stirrer/hot
plate (Corning; Corning, NY) at room temperature until dissolved. The 10.0% TA
solution was then sterile filtered under vacuum using a 150 mL bottle top filter (Corning;
Corning, NY) and a 1000 mL Pyrex storage/media bottle (Fisher Scientific; Fair Lawn,
NJ). Another 150 mL bottle top filter (Corning; Corning, NY) and 1000 mL Pyrex
storage/media bottle (Fisher Scientific; Fair Lawn, NJ) were used to sterile filter 189 mL
of deionized water filtered using a milliQ system (millipore Direct 8; Darmstadt,
Germany). In order to make a 1.0% (mass/volume) TA solution, 11 mL of the sterilefiltered 10.0% TA solution were added to 99 mL of the sterile-filtered milliQ water in a
new storage/media bottle. Then, 10 mL of the 1.0% TA solution were added to the
remaining 90 mL of sterile-filtered milliQ water, yielding a 0.1% (mass/volume) TA
solution.
Alginate/collagen beads in the CaCl2 solution were then strained using an
autoclaved strainer. The volume of beads was divided into thirds. Each of the 3
storage/media bottles containing 10.0% TA solution, 1.0% TA solution, and 0.1% TA
solution received 1/3 of the total number of alginate/collagen beads. The storage/media
bottles were then placed on a rocker (VWR; Radnor, PA) overnight at a speed setting of
18 to ensure cross-linking of the collagen within the beads.
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A 50 mM sodium citrate solution was made by dissolving 3.9 g of sodium citrate
(Fisher Scientific; Fair Lawn, NJ) into 300 mL of deionized water filtered using a milliQ
system (millipore Direct 8; Darmstadt, Germany). The solution was mixed using a stir
bar (VWR; Radnor, PA) on a stirrer/hot plate (Corning; Corning, NY) at room
temperature until dissolved. The solution was then sterile filtered under vacuum using a
1000 mL bottle top filter (Corning; Corning, NY) and a 1000 mL Pyrex storage/media
bottle (Fisher Scientific; Fair Lawn, NJ). The sterile-filtered sodium citrate solution was
then divided equally into 3 storage/media bottles. The collagen beads from the 3
storage/media bottles containing TA cross-linking solutions were then strained using an
autoclaved strainer and transferred to the corresponding storage/media bottle containing
100 mL of 50 mM sodium citrate solution. The storage/media bottles were then placed on
a rocker (VWR; Radnor, PA) for 3 hrs.
After 3 hrs in the sodium citrate solution, the collagen beads were strained using
an autoclaved strainer and transferred to corresponding 50 mL centrifuge tubes (Corning;
Corning, NY) containing 10 mL of Dulbecco’s Phosphate Buffered Saline (PBS) (Sigma
Aldrich; St. Louis, MO). The beads were then stored at 20 oC until further use.

2.2 Cell Culture
SW872, BT474, and MCF10A cells obtained from ATCC (Manassas, VA) were
cultured in T-75 culture flasks (Corning; Corning, NY) under sterile conditions. For the
SW872 cell line, Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12
(DMEM/F12) (ATCC; Manassas, VA) was used. For the BT474 cell line, Dulbecco’s
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Modified Eagle Medium (DMEM) (ATCC; Manassas, VA) was used. For the MCF10A
cell line, Dulbecco’s Modified Eagle Medium (DMEM) (ATCC; Manassas, VA)
supplemented with MEGM SingleQuots (Lonza; Walkersville, MD) was used. In
addition, each media type was enhanced with 10.0% fetal bovine serum (FBS) (Corning;
Manassas, VA), 1.0% antibiotic-atimycotic (AA) (Gibco; Great Island, NY), and 0.2%
fungizone (Gibco; Great Island, NY). The cells were incubated at 37 oC with 5.0% CO2
in a MCO-18AIC incubator (Sanyo Scientific; Wood Dale, IL).

2.3 Cell Seeding on Collagen Beads
SW872 cells were passaged and resuspended in 10 mL of media. A
hemocytometer (Fisher Scientific; Fair Lawn, NJ) and Axiovert 40 CFL microscope
(Zeiss; Oberkochen, Germany) were used to determine the concentration of the SW872
cell suspension. The hemocytometer was loaded with 10 μL of the cell suspension and
placed on the microscope stage. The 10X objective lens was used with a 10X eyepiece,
yielding a total magnification of 100X. The coarse focus and fine focus were adjusted as
necessary to bring the hemocytometer counting grid loaded with SW872 cells into focus.
Cells within the four large corner squares were counted. This process was repeated for
the other counting grid of the hemocytometer, and the two cell counts were averaged.
This number was then divided by 4 in order to obtain the average number of cells per
large square. The volume of this square is 100 nL; therefore, this number corresponds to
the average number of cells per nL. This value was then multiplied by 10,000 in order to
convert it to the average number of cells per mL. Finally, the average cell concentration
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was multiplied by the total volume of the cell suspension in order to determine the total
number of cells in the original sample.
Collagen beads cross-linked with TA in concentrations of 10.0% (mass/volume),
1.0%, and 0.1% and stored in Dulbecco’s Phosphate Buffered Saline (PBS) (Sigma
Aldrich; St. Louis, MO) were removed from storage, and centrifuged at 500 rpm for 5
minutes using an Allegra X-12R centrifuge (Beckman Coulter; Indianapolis, IN). The
PBS was then aspirated from the 50 mL centrifuge tubes (Corning; Corning, NY). A 1001000 μL VWR Signature Ergonomic High Performance Single-Chanell Variable Volume
pipettor (VWR; Radnor, PA) was used to transfer 500 μL of each concentration of
collagen cross-linked beads to 50 mL TubeSpin Bioreactor 50 roller tubes (Techno
Plastic Products AG; Trasadingen, Switzerland) in triplicate, for a total of 9 tubes. The
end of the pipette tip was cut using scissors to prevent any damages to the collagen beads
during pipetting.
From the SW872 cell suspension, 1.5 x 106 cells were added to each roller tube
based on the determination of the cell concentration from the hemocytometer.
Supplemented (as described above) Dulbecco’s Modified Eagle Medium: Nutrient
Mixture F-12 (DMEM/F12) (ATCC; Manassas, VA) was added to each tube for a total
volume of 10 mL per tube.
The roller tubes were then placed in a WSR Bot Drive 7"R 5 x 03 Deck rotating
wheel apparatus (Wheaton; Millville, NJ) and spaced appropriately to ensure even
rotation. This encouraged even cell attachment to the collagen beads and prevented
adhesion of the beads to the tubes. Centrifuge tubes containing water were used for
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balance when necessary. The rotating wheel was placed in the MCO-18AIC incubator
(Sanyo Scientific; Wood Dale, IL) at 37 oC with 5.0% CO2. The rotating switch was then
turned on to initiate rotation. The roller tubes remained in the WSR Bot Drive 7"R 5 x 03
Deck rotating wheel apparatus (Wheaton; Millville, NJ) for 7 days to allow for
attachment and proliferation of the SW872 cells on the beads.
This procedure was repeated using BT474 cells.

2.4 LIVE/DEAD Viability-Cytotoxicity Assay
After 7 days of incubation time in the WSR Bot Drive 7"R 5 x 03 Deck rotating
wheel apparatus (Wheaton; Millville, NJ), roller tubes containing collagen beads crosslinked with TA in concentrations of 10.0% (mass/volume), 1.0%, and 0.1% and seeded
with SW872 cells were removed from the incubator. The roller tubes were centrifuged at
500 rpm for 5 minutes using an Allegra X-12R centrifuge (Beckman Coulter;
Indianapolis, IN), and the media was aspirated from the tubes. Next, 25 mL of
Dulbecco’s Phosphate Buffered Saline (PBS) (Sigma Aldrich; St. Louis, MO) were
added to each roller tube. The roller tubes were centrifuged again at 500 rpm for 5
minutes using an Allegra X-12R centrifuge (Beckman Coulter; Indianapolis, IN), and the
PBS was aspirated from the tubes.
Using a Molecular Probes LIVE/DEAD Viability/Cytotoxicity kit for mammalian
cells (Fisher Scientific; Fair Lawn, NJ), a 10 μM Ethidium homodimer-1 (EthD-1) and 10
μM Calcein AM working solution was made by adding 25 μL of 2mM EthD-1 to 5 mL of
Dulbecco’s Phosphate Buffered Saline (PBS) (Sigma Aldrich; St. Louis, MO) in a 15 mL
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centrifuge tube (Corning; Corning, NY). Then 12.5 μL of 4 mM calcein AM were added
to the solution. The working solution was the vortexed for 10 s using a VWR Analog
Vortex Mixer (VWR; Radnor, PA).
Next, 300 μL of the working solution were added to each roller tube containing
collagen beads cross-linked with TA in concentrations of 10.0% (mass/volume), 1.0%,
and 0.1% and seeded with SW872 cells. The SW872 loaded collagen cross-linked beads
were allowed to incubate in the dark for 45 min at room temperature. After the incubation
period was over, 10 μL of the working solution were added to each roller tube.
A 100-1000 μL VWR Signature Ergonomic High Performance Single-Chanell
Variable Volume pipettor (VWR; Radnor, PA) was used to transfer 150 μL of collagen
cross-linked beads to microscope slides (Fisher Scientific; Fair Lawn, NJ). The end of the
pipette tip was cut using scissors to prevent any damages to the collagen beads during
pipetting. An Axiovert 40 CFL microscope (Zeiss; Oberkochen, Germany) was used to
view the collagen beads under fluorescence, and an Axiocam MRc5 (Zeiss; Overkochen,
Germany) was used image the collagen beads.
This procedure was repeated for collagen beads cross-linked with TA in
concentrations of 10.0% (mass/volume), 1.0%, and 0.1% and seeded with BT474 cells.

2.5 Co-Culture of BT474 cells and SW872 seeded TA crosslinked Collagen Beads
BT474 cells were passaged and resuspended in 10 mL of media. A
hemocytometer (Fisher Scientific; Fair Lawn, NJ) and Axiovert 40 CFL microscope
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(Zeiss; Oberkochen, Germany) were used to determine the concentration of the BT474
cell suspension according to the previously described method on pages 25-26.
From the BT474 cell suspension, 1.0 x 105 cells were added to each well in Costar
24-well Transwell® plates (Corning; Corning, NY) for a total of 36 wells based on the
determination of the number of cells per mL from the hemocytometer. Supplemented (as
described above) Dulbecco’s Modified Eagle Medium (DMEM) (ATCC; Manassas, VA)
was added to each well for a total volume of 500 μL per well. Transwell® permeable
supports with a 0.4 μm polycarbonate membrane were placed in all wells except the well
of the first row. The first row of wells acted as the control groups. The Transwell® plates
were then placed in the MCO-18AIC incubator (Sanyo Scientific; Wood Dale, IL) at
37oC with 5.0% CO2 overnight to allow the cells to attach to the surface of the well
plates. The experimental setup and design are shown in Figures 2.3 and 2.4.
After 7 days of incubation time in the WSR Bot Drive 7"R 5 x 03 Deck rotating
wheel apparatus (Wheaton; Millville, NJ), roller tubes containing collagen beads crosslinked with TA in concentrations of 10.0% (mass/volume), 1.0%, and 0.1% and seeded
with SW872 cells were removed from the incubator. The roller tubes were centrifuged at
500 rpm for 5 minutes using an Allegra X-12R centrifuge (Beckman Coulter;
Indianapolis, IN), and the media was aspirated from the tubes. A 100-1000 μL VWR
Signature Ergonomic High Performance Single-Chanell Variable Volume pipettor
(VWR; Radnor, PA) was used to transfer 100 μL of collagen cross-linked beads from
each roller tube to Transwell® permeable supports in triplicate, for a total of 9 wells per
concentration of TA cross-linked collagen beads. The end of the pipette tip was cut using
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scissors to prevent any damages to the collagen beads during pipetting. The Transwell®
plates were then placed in the MCO-18AIC incubator (Sanyo Scientific; Wood Dale, IL)
at 37oC with 5.0% CO2. Samples were taken on days 3, 5, and 7.
This entire procedure was repeated in order to analyze other sample types.
This method was also modified in order to incorporate the co-culture of MCF10A
cells and SW872 seeded TA cross-linked collagen beads in addition to the co-culture of
BT474 cells and SW872 seeded TA cross-linked collagen beads. The modified
experimental setup in shown in Figure 2.5.
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Figure 2.3: Experimental Setup
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Figure 2.4: Experimental Design

Figure 2.5: Modified Experimental Setup
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2.6 Sample Collection
After co-culturing BT474 cells with SW872 seeded TA cross-linked collagen
beads, samples were collected on Days 3, 5, and 7. The following methods were
conducted for each time point.
2.6.1 Experiment 1
2.6.1.1 Media Collection
The media was removed from the 12 wells in the 24 well-plate that corresponded
to the appropriate time point as shown in Figure 2.3 using a 100-1000 μL VWR Signature
Ergonomic High Performance Single-Chanell Variable Volume pipettor (VWR; Radnor,
PA) and placed in corresponding microcentrifuge tubes (Fisher Scientific; Fair Lawn,
NJ). The microcentrifuge tubes were then stored in the freezer at 4 oC.
2.6.1.2 Trypan Blue Staining
After the media was removed, 250 μL of 0.05% Trypsin, 0.53 mM EDTA, 1X [-]
sodium bicarbonate (Corning; Manassas, VA) were added to each of the corresponding
12 wells. The well-plate was then placed in a MCO-18AIC incubator (Sanyo Scientific;
Wood Dale, IL) for 5 min at 37 oC with 5.0% CO2. Next, 250 μL of Dulbecco’s Modified
Eagle Medium (DMEM) (ATCC; Manassas, VA) supplemented with 10.0% fetal bovine
serum (FBS) (Corning; Manassas, VA), 1.0% antibiotic-atimycotic (AA) (Gibco; Great
Island, NY), and 0.2% fungizone (Gibco; Great Island, NY) were added to each well. A
100-1000 μL VWR Signature Ergonomic High Performance Single-Chanell Variable
Volume pipettor (VWR; Radnor, PA) was used to resuspend the cells and ensure that
they had detached from the surface of the well-plate. Then, 10 μL of each cell suspension
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were added to microcentrifuge tubes containing 40 μL of Trypan Blue (Modified) 0.4%
solution 1.0N phosphate buffered saline (Trypan Blue) (MP Biomedicals; Solon, Ohio),
and the solution was mixed.
2.6.1.3 Protein Isolation
The remainders of the cell suspensions were transferred to microcentrifuge tubes,
combining all control cell suspensions, 10.0% TA treated cell suspensions, 1.0% TA
treated cell suspensions, and 0.1% TA treated cell suspensions into corresponding tubes.
The cell suspensions were centrifuged at 5000 rpm for 5 min using a Sorvall Legend
Micro 21R centrifuge (Fisher Scientific; Fair Lawn, NJ). A working solution was made
by mixing 800 μL of Mammalian Protein Extraction Reagent (M-PER) (Fisher Scientific;
Rockford, IL) with 8 μL of Halt Protease Inhibitor Cocktail, EDTA-free (100X) (Fisher
Scientific; Rockford, IL) and 8 μL of Halt Phosphatase Inhibitor Cocktail (100X) (Fisher
Scientific; Rockford, IL). Then, 200 μL of the working solution were added to each of the
microcentrifuge tubes, and the tubes were allowed to incubate for 10 min at room
temperature. The microcentrifuge tubes were then centrifuged for 10 min at 10,000 rpm
at 4 oC using a Sorvall Legend Micro 21R centrifuge (Fisher Scientific; Fair Lawn, NJ).
After centrifugation, the protein samples were stored in the freezer at -20oC.
2.6.2 Experiment 2
2.6.2.1 Media Collection
The media was collected as previously described on pages 32-33.
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2.6.2.2 RNA Precipitation
After the media was removed, 250 μL of 0.05% Trypsin, 0.53 mM EDTA, 1X [-]
sodium bicarbonate (Corning; Manassas, VA) were added to each of the corresponding
12 wells. The well-plate was then placed in a MCO-18AIC incubator (Sanyo Scientific;
Wood Dale, IL) for 5 min at 37 oC with 5.0% CO2. Next, 250 μL of Dulbecco’s Modified
Eagle Medium (DMEM) (ATCC; Manassas, VA) supplemented with 10.0% fetal bovine
serum (FBS) (Corning; Manassas, VA), 1.0% antibiotic-atimycotic (AA) (Gibco; Great
Island, NY), and 0.2% fungizone (Gibco; Great Island, NY) were added to each well. A
100-1000 μL VWR Signature Ergonomic High Performance Single-Chanell Variable
Volume pipettor (VWR; Radnor, PA) was used to resuspend the cells and ensure that
they had detached from the surface of the well-plate. The cell suspensions were
transferred to microcentrifuge tubes and centrifuged at 1000 rpm for 5 min using a
Sorvall Legend Micro 21R centrifuge (Fisher Scientific; Fair Lawn, NJ) in order to lyse
the cells. The media was then aspirated from the microcentrifuge tubes, and the cells
were resuspended in 200 μL of TRIzol reagent (Fisher Scientific; Fair Lawn, NJ). The
tubes were allowed to incubate at room temperature for 10 min. The microcentrifuge
tubes were stored in the freezer at 4 oC.
The SW872 seeded TA cross-linked collagen beads were removed from the
Transwell® permeable supports using a 100-1000 μL VWR Signature Ergonomic High
Performance Single-Chanell Variable Volume pipettor (VWR; Radnor, PA) and
transferred to corresponding microcentrifuge tubes. The end of the pipette tip was cut
using scissors to ensure that all beads were collected. The microcentrifuge tubes were
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then centrifuged at 1000 rpm for 5 min using a Sorvall Legend Micro 21R centrifuge
(Fisher Scientific; Fair Lawn, NJ) in order to lyse the cells. The media was then aspirated
from the microcentrifuge tubes. Next, 200 μL of TRIzol reagent (Fisher Scientific; Fair
Lawn, NJ) were added to each microcentrifuge tube, and the tubes were allowed to
incubate at room temperature for 10 min. The microcentrifuge tubes were stored in the
freezer at 4 oC.
2.6.3 Experiment 3
In addition to BT474 cells, MCF10A cells were co-cultured with SW872 seeded
TA cross-linked collagen beads as shown in Figure 2.5.
2.6.3.1 Media Collection
The media was collected as previously described on pages 32-33.
2.6.3.2 Trypan Blue Staining
After the media was removed, cells were stained with Trypan Blue according to
the method previously described on page 33.
2.6.3.3 Protein Isolation
Protein was isolated from the cells according to the protocol previously described
in section 2.6.1.3.

2.7 Trypan Blue Exclusion Cell Viability Assay
Cell suspensions stained with Trypan Blue were assessed using a hemocytometer
(Fisher Scientific; Fair Lawn, NJ) and Axiovert 40 CFL microscope (Zeiss; Oberkochen,
Germany) as previously described on pages 25-26. Live cells remained unstained due to
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intact cellular membranes while dead cells were stained blue due to lost membrane
integrity. Based on this difference in staining, live cells and dead cells within the large
center square were counted. This process was repeated for the other counting grid of the
hemocytometer, and both the live cell counts and dead cell counts were averaged. These
numbers were then multiplied by the dilution factor of 5 since 10 μL of the cell
suspensions were added to 40 μL of Trypan Blue. Finally, the average live cell
concentration and dead cell concentration were multiplied by the total volume of the cell
suspension (0.5 mL) in order to determine the total number of live cells and dead cells in
the original sample.

2.8 Folin-Ciocalteu Assay
A Folin-Ciocalteu (F-C) assay was used to quantify the concentration of TA in the
media below Transwell® inserts containing SW872 loaded TA cross-linked collagen
beads.
First, a 10.0% (mass/volume) TA standard was made by dissolving 1.0 g of tannic
acid (Sigma Aldrich; St. Louis, MO) in 10 mL of Dulbecco’s Modified Eagle Medium
(DMEM) (ATCC; Manassas, VA). Serial dilutions were then performed in order to
obtain TA standards of 5.0%, 2.5%, 1.25%, 0.625%, 0.313%, 0.156%, 0.0781%,
0.0391%,

0.0195%,

0.00977%,

0.00488%,

0.000305%, 0.000153%, and 0.0%.
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0.00244%,

0.00122%,

0.000610%,

A 10.0% (volume/volume) F-C reagent (Sigma Aldrich; St. Louis, MO) solution
was prepared in milliQ water. In addition, a 700 mM sodium carbonate (Fisher Scientific;
Fair Lawn, NJ) solution was prepared in milliQ water.
Next, 100 μL of each TA standard and each media sample were transferred to
microcentrifuge tubes (Fisher Scientific; Fair Lawn, NJ). Then, 200 μL of the 10.0%
(volume/volume) F-C reagent were added to each tube. The tubes were vortexed using a
VWR Analog Vortex Mixer (VWR; Radnor, PA). After mixing, 800 μL of the 700 mM
sodium carbonate solution were added to each microcentrifuge tube. Tubes were vortexed
again using a VWR Analog Vortex Mixer (VWR; Radnor, PA). The tubes were then
allowed to incubate at room temperature for 2 hours.
After incubating, 200 μL of each TA standard and each media sample were
transferred in triplicate into a 96 well-plate (Corning; Corning, NY). The absorbance was
measured at 765 nm on a Synergy Mx microplate reader (BioTek; Winooski, VT). A
standard curve was generated using the Gen5 program (BioTek; Winooski, VT), and the
total TA concentrations for each sample were outputted.

2.9 RNA Isolation
First, samples resuspended in 200 μL of TRIzol reagent (Fisher Scientific; Fair
Lawn, NJ) were removed from the freezer and thawed in a MCO-18AIC incubator
(Sanyo Scientific; Wood Dale, IL) at 37 oC with 5.0% CO2.
Next, the RNA isolation procedure from the TRIzol reagent manual (Fisher
Scientific; Fair Lawn, NJ) was followed according to the manufacturer’s guidelines.
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Note, the manual provides volumes in terms of volume per 1 mL of TRIzol reagent used.
Samples were resuspended in 200 μL of TRIzol reagent; therefore, these volumes were
divided by 5 in order to achieve the necessary volumes for my samples.

2.10 DNA Removal
RNA samples were thawed. Then, the TURBO DNA-free procedure from the
TURBO DNA-free Kit manual (Fisher Scientific; Fair Lawn, NJ) was followed according
to the manufacturer’s guidelines in order to remove any contaminating DNA, remaining
DNase, and divalent cations which can catalyze RNA degradation upon heating.

2.11 RNA Concentration Quantification
A NanoDrop 2000 spectrophotometer (Fisher Scientific; Radnor, PA) was used
according to the manufacturer’s guideline to determine the concentration of RNA in each
sample.

2.12 Reverse Transcription
An Applied Biosystems High-Capacity cDNA Reverse Transcription Kit (Fisher
Scientific; Radnor, PA) was used to convert RNA to single-stranded cDNA. The manual
was followed according to the manufacturer’s guidelines. The RNA concentrations
determined from the Nanodrop were used to calculate the mass of RNA and the volume
of RNase-free water to be added to each well for a total RNA sample volume of 10 μL
with 3.55 μg of RNA.
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2.13 Real-Time Polymerase Chain Reaction
A QuantiTect SYBR Green PCR Kit (Qiagen; Hilden, Germany) and PrimeTime
qPCR primers (Integrated DNA Technologies; Coralville, IA) were used. Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) was used as the housekeeping gene, and caspases
3, 7, and 9 were targeted. Single-stranded cDNA samples were analyzed in replicates for
each gene. The number of samples per gene was determined, and the working master mix
for each gene was prepared based on the following calculations:
Samples per gene (including negative control) + 1 = Total Number
Total Number x 10 = μL 2x Qiagen SYBR Green Master Mix
Total Number x 2 = μL PrimeTime assay for each gene
Total Number x 6 = μL Nuclease Free Water
Then, 18 μL of the working master mix was pipetted into each well of a
MicroAmp Fast Optical 96-well reaction plate (Fisher Scientific; Fair Lawn, NJ). Next, 2
μL of each cDNA sample and nuclease free water (negative control) were transferred to
the appropriate well in duplicate. An optical adhesive cover (Fisher Scientific; Fair Lawn,
NJ) was placed on the reaction plate. The plate was run using an Applied Biosystems
StepOnePlus Real-Time PCR System (Fisher Scientific; Fair Lawn, NJ) according to the
following protocol:
1.

Holding: 95 oC for 15 minutes

2.

Cycling: 35 cycles
a.

Denature: 94 oC for 15 seconds

b.

Anneal: 60 oC for 20 seconds
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c.
3.

Extend: 72 oC for 20 seconds

Melt: 70-99 oC ramping

2.14 Bicinchoninic Acid Assay
In order to quantify the total amount of protein in a sample, a Pierce BCA Protein
Assay Kit (Thermo Scientific; Rockford, IL) was used. The microplate procedure was
followed. Diluted albumin standards were prepared according to the protocol, using milliQ water as the diluent. The BCA working reagent was prepared by mixing BCA reagent
A with BCA reagent B 50:1. The diluted albumin standards and the unknown samples
were transferred to a microplate in duplicate. Sample size was limited; therefore, only 10
μL of standards and unknown samples were transferred to each well. Next, 200 μL of the
working reagent were added to each well, and the plate was mixed on a mini shaker
(VWR; Radnor, PA) for 30 seconds. The plate was then incubated at 37 oC with 5.0%
CO2 in a MCO-18AIC incubator (Sanyo Scientific; Wood Dale, IL) for 30 minutes. The
plate was removed from the incubator and cooled to room temperature. The absorbance
was measured at 562 nm on a Synergy Mx microplate reader (BioTek; Winooski, VT). A
standard curve was generated using the Gen5 program (BioTek; Winooski, VT), and the
total protein concentrations for each sample were outputted.
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2.15 Western Blotting
2.15.1 Protein Separation via SDS-PAGE
Protein lysate samples from Experiment 2 were thawed. The BCA assay data was
used to calculate the necessary volume of each sample such that it would contain 20 μg of
protein. The appropriate volumes were then measured into microcentrifuge tubes (Fisher
Scientific;

Fair

Lawn,

NJ).

Laemmli

Sample

Buffer

(Bio-

Rad Laboratories, Inc.; Hercules, CA) was added to each microcentrifuge tube for a total
volume of 45 μL per tube. The microcentrifuge tubes were incubated in a heatblock
(VWR; Radnor, PA) at 95oC for 10 minutes. The tubes were removed using tweezers and
were centrifuged briefly using a Spectrafuge Mini (Labnet International, Inc.;
Woodbridge, NJ). An 18 well Criterion TGX Precast gel (Bio-Rad Laboratories, Inc.;
Hercules, CA) was positioned in a Criterion Cell system (Bio-Rad Laboratories, Inc.;
Hercules, CA) containing 1x Tris-Glycine-SDS running buffer (Bio-Rad Laboratories,
Inc.; Hercules, CA). Next, 10 μL of the Precision Plus Protein Kaleidoscope (Bio-Rad
Laboratories, Inc.; Hercules, CA) were loaded in the first well using a 20-200 μL VWR
Signature Ergonomic High Performance Single-Chanell Variable Volume pipettor
(VWR; Radnor, PA). The same pipettor was used to load the samples into the subsequent
wells. The Criterion Cell system was plugged into the PowerPac Basic (Bio-Rad
Laboratories, Inc.; Hercules, CA), and the gel was run for 45 minutes at 200 V.
2.15.2 Protein Blotting
After running, the precast gel was removed, and the case was cracked open. A
scalpel was used to cut the gel to size based on the loaded wells. The gel was then placed
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in a dish containing 1x Tris-Glycine transfer buffer (Bio-Rad Laboratories, Inc.;
Hercules, CA) and allowed to incubate at room temperature for 15 minutes. A Trans-Blot
SD Semi-Dry Transfer Cell (Bio-Rad Laboratories, Inc.; Hercules, CA) was used to
transfer the blot to the membrane. Extra thick blot paper (Bio-Rad Laboratories, Inc.;
Hercules, CA) was soaked in the transfer buffer and placed on the anode plate assembly
of the Trans-Blot SD Semi-Dry Transfer Cell. Next, a 0.45 um nitrocellulose membrane
(Bio-Rad Laboratories, Inc.; Hercules, CA) was soaked in the transfer buffer and placed
on top of the extra thick blot paper. The precast gel was then placed on top of the
membrane. Another layer of extra thick blot paper was soaked in transfer buffer and
layered on top of the gel. Finally, the cathode plate assembly was latched into place, and
the safety lid was secured. The Trans-Blot SD Semi-Dry Transfer Cell was run at 15 V
for 30 minutes using a PowerPac HC (Bio-Rad Laboratories, Inc.; Hercules, CA).
2.15.3 Protein Detection
The membrane was then removed and transferred to a petri dish containing 15 mL
of 5.0% (mass/volume) milk block solution. The milk block solution consisted of instant
nonfat dry milk (Nestlé Baking; Solon, OH) dissolved in Dulbecco’s Phosphate Buffered
Saline (Sigma Aldrich; St. Louis, MO). The membrane was incubated in the milk block
solution for 1 hour on a mini shaker (VWR; Radnor, PA) at room temperature. The
primary antibody was then diluted in the milk block solution 1:1000, and the membrane
was incubated on an IKA Vibrax VXR basic (IKA Works; Staufen, Germany) overnight
at 4oC. The primary and secondary antibodies (Cell Signaling Technology; Danvers, MA)
used are shown in Table 2.1.
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The membrane was then washed 2 times with 0.1% Tween20 (Sigma Aldrich; St.
Louis, MO) in Dulbecco’s Phosphate Buffered Saline (PBS) (Sigma Aldrich; St. Louis,
MO) for 15 minutes on a mini shaker (VWR; Radnor, PA). Next, the secondary antibody
was diluted 1:2500 in 15 mL of the milk block solution, and the membrane was incubated
on the mini shaker at room temperature for 1.5 hr. The membrane was washed 2 times
with 0.1% Tween20 in PBS for 15 minutes on the mini shaker. The chemiluminescence
substrate was prepared by mixing 0.75 mL of 20x LumiGlo Reagent (Cell Signaling
Technology; Danvers, MA) and 0.75 mL of 20x Peroxide (Cell Signaling Technology;
Danvers, MA) with 13.5 mL of milli-Q water. The chemiluminescence substrate was then
added to the membrane and incubated on a mini shaker at room temperature for 2 min.
The excess substrate was removed using a Kimwipe, and the membrane was imaged
using a FluorChem M (Cell Biosciences; Santa Clara, CA). The membrane was washed
with 0.1% Tween20 in PBS for 5 minutes on a mini shaker and stored in PBS at 4oC.
Primary Antibody
β-Actin (13E5) Rabbit mAb (HRP Conjugate)

Secondary Antibody
HRP Conjugated to Primary Ab

Caspase-3 Rabbit Ab

Anti-rabbit IgG, HRP-linked Ab

Cleaved caspase-3 (D175) (5A1E) Rabbit mAb

Anti-rabbit IgG, HRP-linked Ab

Caspase-7 Rabbit Ab

Anti-rabbit IgG, HRP-linked Ab

Cleaved caspase-7 (Asp198) (D6H1) Rabbit mAb

Anti-rabbit IgG, HRP-linked Ab

Caspase-9 (Human Specific) Rabbit Ab

Anti-rabbit IgG, HRP-linked Ab

Cleaved caspase-9 (D330) (Human Specific) Rabbit
Anti-rabbit IgG, HRP-linked Ab
mAB
Table 2.1: Primary and Secondary Antibodies used for Western Blots
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2.15.4 Western Blot Stripping
The PBS was removed from the membrane, and the membrane was washed with
0.1% Tween20 in PBS for 5 minutes. The membrane was stripped by diluting western
blot stripping buffer B (Santa Cruz Biotechnology; Dallas, TX) in western blot stripping
buffer A (Santa Cruz Biotechnology; Dallas, TX) 1:100. 200 μL of substrate B were
added to 20 mL of substrate A and transferred to the membrane. The membrane was
incubated with the stripping substrate on a mini shaker at room temperature for 30
minutes. The membrane was washed 3 times with 0.1% Tween20 in PBS for 5 minutes
on the mini shaker. The protein detection procedure was repeated for all proteins of
interest.
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CHAPTER THREE
RESULTS AND DISCUSSION
3.1 LIVE/DEAD Viability-Cytotoxicity Assay
3.1.1 TA crosslinked Collagen Beads Seeded with SW872 cells
After seeding collagen beads with SW872 cells, LIVE/DEAD assays were
conducted to assess the cell viability. This assay stains live cells green and dead cells red
allowing for visualization and quantification of cell viability. The results of the
LIVE/DEAD assay of collagen beads seeded with human adipocytes are shown in
Figures 3.1 and 3.2. The LIVE/DEAD assay reveals that the most successful cell seeding
of the three groups tested occurs with the 0.1% TA crosslinked collagen beads. It also
shows the high toxicity level of the 10.0% TA to the human adipocytes; therefore,
confirming the 10.0% TA group as a negative control.

Figure 3.1: SW872 Cell Viability for different TA crosslinking concentrations, *p<0.05
between 10.0% TA and 1.0% TA, **p<0.05 between 1.0% TA and 0.1% TA
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Figure 3.2: LIVE/DEAD images of SW872 loaded TA crosslinked Collagen beads,
Scale bars = 100 μm

3.1.2 TA crosslinked Collagen Beads Seeded with BT474 cells
The results of the LIVE/DEAD assay of collagen beads seeded with human
HER2+ breast cancer cells are shown in Figures 3.3-3.6. The results parallel the results of
the LIVE/DEAD assay of collagen beads seeded with human adipocytes. The most
successful cell seeding occurs with the 0.1% TA crosslinked collagen beads. The 10.0%
TA group is very toxic to the HER2+ breast cancer cells and again, acts as a positive
control. Comparing the results of the LIVE/DEAD assay of collagen beads seeded with
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the two different cell lines reveals that TA is significantly more toxic to human HER2+
breast cancer cells than human adipocytes.

Figure 3.3: BT474 Cell Viability on Collagen beads Day 3, *p<0.05 between 10.0% TA
and 1.0% TA, **p<0.05 between 1.0% TA and 0.1% TA
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Figure 3.4: BT474 Cell Viability on Collagen beads Day 6, *p<0.05 between 10.0% TA
and 1.0% TA, **p<0.05 between 1.0% TA and 0.1% TA

Figure 3.5: BT474 Cell Viability on Collagen beads Day 9, *p<0.05 between 10.0% TA
and 1.0% TA, **p<0.05 between 1.0% TA and 0.1% TA
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Figure 3.6: LIVE/DEAD images of BT474 loaded TA crosslinked Collagen beads, Scale
bars = 100 μm

3.2 Trypan Blue Exclusion Assay
3.2.1 BT474 cells grown beneath TA crosslinked Collagen Beads
After co-culturing human HER2+ breast cancer (BT474) cells with human
adipocyte (SW872) seeded TA cross-linked collagen beads, a Trypan Blue exclusion
assay was conducted. The Trypan Blue exclusion assay allows for visualization and
quantification of cell viability due to its permeability of dead cells. The cellular
membrane of live cells is intact; therefore, it is impermeable to substances such as the
Trypan Blue stain. However, as a cell begins undergoing apoptosis, the integrity of its
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cellular membrane is lost, making it permeable to the Trypan Blue stain. In summary, the
Trypan Blue penetrates the cellular membrane of dead cells, staining them blue, while
live cells remain unstained. This was used to assess the viability of the BT474 cells
grown beneath SW872 seeded TA cross-linked collagen beads and to evaluate the effects
of the three TA groups on the BT474 cells over time. The results are shown in Figure 3.7.
The results indicate that TA released from the remodeling of TA crosslinked collagen
beads by SW872 cells inhibits cell growth in BT474 cells at all TA concentrations tested
with a p-value < 0.05. It was also shown that TA toxicity increases over time at all TA
concentrations tested with a p-value < 0.05.

Figure 3.7: BT474 Growth and Proliferation, *p<0.05 between control and TA groups
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3.2.2 MCF10A cells grown beneath TA crosslinked Collagen Beads
The Trypan Blue exclusion assay was also used to assess the viability of
MCF10A cells grown beneath SW872 seeded TA cross-linked collagen beads and to
evaluate the effects of the three TA groups on the MCF10A cells over time. The results
are shown in Figures 3.8-3.10. The results indicate that TA released from the remodeling
of TA crosslinked collagen beads by SW872 cells do not inhibit cell growth in MCF10A
cells at TA concentrations of 1.0% and 0.1% with a p-value > 0.05. The 10.0% TA group
does inhibit cell growth in MCF10A cells which is expected due to the high toxicity of
10.0% TA. It was also shown that TA toxicity does not increase over time at all TA
concentrations tested with a p-value > 0.05, again indicating the resistance of MCF10A
cells to TA toxicity.

Figure 3.8: MCF10A Cell Viability after 3 days of TA exposure, *p<0.05 between
10.0% TA group and other groups
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Figure 3.9: MCF10A Cell Viability after 5 days of TA exposure, *p<0.05 between
10.0% TA group and other groups

Figure 3.10: MCF10A Cell Viability after 7 days of TA exposure, *p<0.05 between
10.0% TA group and other groups
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3.3 Folin-Ciocalteu Assay
A Folin-Ciocalteu assay was conducted in order to quantify the concentration of
TA in the media below the Transwell® inserts containing TA crosslinked collagen type I
beads of various concentrations. It is important to understand the release profile of TA
from the collagen type I crosslinked beads as well as determine the minimum
concentration of TA for apoptosis induction. The F-C assay is a colorimetric assay in
which the F-C reagent, consisting of phosphomolybdate and phosphotungstate, reacts
with phenolic compounds forming a blue complex. The results of the F-C assay are
shown in Figure 3.11.

Figure 3.11: TA levels in Media below SW872 loaded TA crosslinked Collagen Beads,
*p<0.05 between Control and TA groups
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Figure 3.11 shows a statistically significant difference (p<0.05) in the
concentration of TA is the control group as compared to each of the TA groups. There is
not a statistical significance in the TA concentration found in the media among the TA
groups tested; however, a decreasing trend is observed as the TA crosslinking
concentration decreases.
It is important to note that the F-C reagent reacts with components of the media;
therefore, creating a false positive for the presence of phenolic compounds in the media
alone. This rationale provides an explanation for a concentration of around 0.0054 %TA
(mass/volume) in the control group seen in Figure 3.11. The F-C assay also revealed the
relatively small concentrations of TA required to interfere with cell growth and
proliferation of BT474 cells. This is important in determining the ideal crosslinking TA
concentration, while minimizing toxicity to normal human breast epithelial tissue.

3.4 Real-time Polymerase Chain Reaction
After showing that TA inhibits cell growth in BT474 cells, Real-time PCR was
used to evaluate the mechanisms of this inhibition. Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) was used as a housekeeping gene, and caspase 3, 7, and 9
primers were used as indicators of apoptosis. The results showed no significant
expression of caspase 3, 7, or 9 among the 10.0% TA group. This could be attributed to
the high toxicity of 10.0% TA, which would yield very little caspase micro-RNA
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isolation from the BT474 cells for analyzation through Real-time PCR. Fold change data
in caspase 3 expression for the other two TA groups in shown in Figure 3.12.

Figure 3.12: Fold change in expression of executioner caspase 3,*p<0.05 between 1.0%
TA and Control, **p<0.05 between 0.1% TA and 1.0% TA

Figure 3.12 shows a statistically significant fold change in the expression of
caspase 3 in the 1.0% TA and 0.1% TA groups as compared to the control with a p-value
< 0.05. It also shows a statistically significant difference in the fold change in the
expression of caspase 3 between the 1.0% TA group and the 0.1% TA group. It was
expected that the fold change would be greater in the 1.0% TA group than the 0.1% TA
group; however, the above results could be attributed to the higher toxicity of the 1.0%
TA group. The higher toxicity would result in increased levels of caspase proteins earlier
during exposure of BT474 cells to TA. The BT474 cell line is known to express X-linked
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inhibitor of apoptosis protein which binds and inhibits active caspases 3, 7, and 9 and
ubiquinates them in response to cellular stress (Foster et al.; 2009). The cells exposed to
the 1.0% TA group experience higher levels of cellular stress than those exposed to the
0.1% TA group; therefore, inducing the action of X-linked inhibitor of apoptosis protein.
As this protein binds and inhibits active caspases, particularly initiator caspase 9, the
downstream levels of executioner caspase decrease. If real-time polymerase chain
reaction were conducted using RNA isolated from the BT474 cells earlier during their
exposure to TA, a higher fold change in the expression of caspase 3 in the 1.0% TA
group would be expected as opposed to the 0.1% TA group because the X-linked
inhibitor of apoptosis protein would not yet be acting on the caspases. Although the
results did not follow the expected trend, the significant fold change in the expression of
caspase 3 in both groups indicates induction of apoptosis by TA via the caspase
pathways.
3.5 Western Blotting
After showing that TA results in significant fold change in the expression of
caspase 3 in the 1.0% and 0.1% TA groups, western blotting was conducted in order to
further assess expression of the caspase proteins by the BT474 cells plated below TA
crosslinked collagen type I beads. In addition, western blotting was conducted using
proteins isolated from MCF10A cells, the normal human breast epithelial cell line, plated
below TA crosslinked collagen type I beads in order to compare the effects of TA on
HER2+ breast cancer cells and normal human breast epithelial cells. The results are
shown in Figures 3.13 and 3.14.
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Figure 3.13: Western Blot for caspase 3, caspase 7, and β-actin, Lane 1: Ladder, Lane 2:
BT474 cells from the control group, Lane 3: BT474 cells from the 10.0% TA group, Lane
4: BT474 cells from the 1.0% TA group, Lane 5: BT474 cells from the 0.1% TA group,
Lane 6: MCF10A cells from the control group, Lane 7: MCF10A cells from the 10.0%
TA group, Lane 8: MCF10A cells from the 1.0% TA group, Lane 9: MCF10A cells from
the 0.1% TA group

Although western blotting was conducted using primary antibodies for cleaved
caspase 3, cleaved caspase 7, caspase 9, and cleaved caspase 9, sufficient expression was
not detected for these proteins; therefore, those western blots are not included in Figure
3.13. It is important to note that initiator caspase 9 is upstream of executioner caspases 3
and 7 and is responsible for their activation; therefore, it is likely that there was
significant caspase 9 expression earlier in the TA exposure timeframe or that the multiple
stripping procedures interfered with the results. The cleaved caspases are smaller than the
caspases, and it is possible that those proteins ran off the gel during the protein separation
via SDS-PAGE step. Further investigation is necessary to determine the effects of TA
exposure on the expression of these proteins by BT474 and MCF10A cells.
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The corresponding relative densitometry units (RDU) for caspase 3 and caspase 7
expression are shown in Figure 3.14. The results do not replicate the results determined
by real-time PCR. They do not show a significant change in the expression of caspases by
BT474 cells exposed to TA in the 1.0% and 0.1% TA groups as compared to the control.
However, the results do show a significant difference in the expression of caspase 3 by
BT474 cells compared to MCF10A cells when exposed to 10.0% TA. Although it is
expected that the fold change in the expression of caspase 3 by MCF10A cells would be
greater after exposure to 10.0% TA due to the high toxicity of this concentration, the
results confirm the higher toxicity of TA to BT474 cells than MCF10A cells.
In order to further characterize the effects of TA exposure on the expression of
caspase proteins by BT474 cells and MCF10A cells, more western blotting analysis is
necessary. It is important to analyze the caspase protein expression over time for both cell
lines tested in order to determine the ongoing effects of TA exposure and define any
resistance to these effects that may exist. It is also important to optimize the western
blotting method including the protein loading concentration and washing in addition to
minimizing membrane exposure and stripping which can alter expression.

BT474

BT474

BT474

BT474

MCF10A

MCF10A

MCF10A

MCF10A

Control

10.0% TA

1.0% TA

0.1% TA

Control

10.0% TA

1.0% TA

0.1% TA

Caspase 3

0.46

0.88

0.33

0.32

0.19

0.16

0.35

0.36

Caspase 7

0.20

0.42

0.20

0.08

0.20

0.37

0.24

0.27

Table 3.1: Relative Densitometry Units for caspase expression by BT474 and MCF10A
cells exposed to TA
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Figure 3.14: Caspase 3 and 7 expression in BT474 and MCF10A cells exposed to TA
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CHAPTER FOUR
CONCLUSIONS
4.1 Conclusions
TA crosslinked collagen type I beads seeded with human adipocyte cells provide
a basis for an injectable soft tissue regeneration matrix with chemotherapeutic properties
against breast cancer. Adipocytes were successfully loaded onto collagen type I beads
with TA crosslinking concentrations of 1.0% and 0.1% as shown using a LIVE/DEAD
viability-cytotoxicity assay, with the most successful adipocyte loading occurring in the
0.1% TA group (Figure 3.2). LIVE/DEAD viability-cytotoxicity assays also revealed the
higher toxicity of TA to HER2+ breast cancer cells as compared to human adipocytes
(Figure 3.6). As adipocytes attach and grow on the TA crosslinked collagen beads, they
remodel the collagen, releasing TA which then interacts with the surrounding
environment as shown through Folin-Ciocalteu assays (Figure 3.11). The toxicity of TA
to HER2+ breast cancer cells was further confirmed using Trypan Blue exclusion assays
which revealed a statistically significant decrease in the number of live cells in all three
groups tested as compared to the control group across 7 days (Figure 3.7). This reduction
in HER2+ cell growth and proliferation is caused by apoptosis induction via the caspase
pathways as shown by real-time PCR and western blotting (Figures 3.12 and 3.13).
Therefore, TA crosslinked collagen type I beads loaded with adipocytes have
demonstrated potential as a novel anti-cancer agent against many breast cancer types
including HER2+ breast cancer.
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4.2 Future Research
In order to move forward for this research project and advance it towards clinical
application, there are several important questions that must be answered through
continued investigation.
First, the size of the TA crosslinked collagen type I beads must be optimized for
injection. In order to achieve the desired injectable property, the beads must be small
enough such that they can be forced through a needle without rupture or compromise of
the bead structure. However, this decrease in bead size must be balanced with cell
seeding ability and longevity in vivo.
The additional components of the injectable matrix also need to be determined.
The current TA crosslinked collagen type I beads must be suspended in a matrix of sorts
in order to ensure delivery of the therapeutic TA to the desired target area. This matrix
will likely be composed of a hydrogel or sol-gel material that is an injectable liquid at
room temperature and a gel or solid at body temperature.
Moving forward, it will also be key to determine the half-life of TA in vivo and
the release profile of TA from the collagen crosslinked beads. This is necessary in order
to maximize therapeutic effects while minimizing local toxicity over time. It will also aid
in determining the optimum TA crosslinking concentration for the collagen crosslinked
beads. The ideal TA crosslinking concentration will enable the highest adipocyte cell
seeding density without compromising the chemotherapeutic effects of TA against the
breast cancer cells.
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We have shown that TA has a chemotherapeutic effect against different types of
breast cancer by inducing apoptosis via the caspase pathways; however, it is important to
better understand the mechanisms of TA action against the breast cancer cell types tested.
This will help to determine the ideal candidates for treatment with this therapy. Better
understanding the therapeutic action of TA will also provide insight into other potential
clinical areas in which this technology could be beneficial such as other soft tissue cancer
types.
After optimizing the conformation of the injectable matrix, in vivo studies should
be conducted in order to confirm the clinical potential of the matrix as a therapeutic
treatment option for breast cancer patients.
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APPENDICES
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Appendix A
Western Blotting

Figure A-1: Western Blot for β-Actin, Lane 1: Ladder, Lane 2: BT474 cells from the
control group, Lane 3: BT474 cells from the 10.0% TA group, Lane 4: BT474 cells from
the 1.0% TA group, Lane 5: BT474 cells from the 0.1% TA group, Lane 6: MCF10A
cells from the control group, Lane 7: MCF10A cells from the 10.0% TA group, Lane 8:
MCF10A cells from the 1.0% TA group, Lane 9: MCF10A cells from the 0.1% TA group
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Figure A-2: Western Blot for caspase 3, Lane 1: Ladder, Lane 2: BT474 cells from the
control group, Lane 3: BT474 cells from the 10.0% TA group, Lane 4: BT474 cells from
the 1.0% TA group, Lane 5: BT474 cells from the 0.1% TA group, Lane 6: MCF10A
cells from the control group, Lane 7: MCF10A cells from the 10.0% TA group, Lane 8:
MCF10A cells from the 1.0% TA group, Lane 9: MCF10A cells from the 0.1% TA group
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Figure A-3: Western Blot for caspase 7, Lane 1: Ladder, Lane 2: BT474 cells from the
control group, Lane 3: BT474 cells from the 10.0% TA group, Lane 4: BT474 cells from
the 1.0% TA group, Lane 5: BT474 cells from the 0.1% TA group, Lane 6: MCF10A
cells from the control group, Lane 7: MCF10A cells from the 10.0% TA group, Lane 8:
MCF10A cells from the 1.0% TA group, Lane 9: MCF10A cells from the 0.1% TA group

71

REFERENCES
American Cancer Society. Breast cancer survival rates by stage. Atlanta: American
Cancer Society; 2016. http://www.cancer.org/cancer/breastcancer/detailedguide/
breast-cancer-survival-by-stage.
American Cancer Society. Cancer Facts & Figures 2016. Atlanta: American Cancer
Society; 2016. http://www.cancer.org/acs/groups/content/@research/documents/
document/acspc-047079.pdf.
American Cancer Society. Chemotherapy for Breast Cancer. Atlanta: American Cancer
Society; 2016. http://www.cancer.org/cancer/breastcancer/detailedguide/breastcancer-treating-chemotherapy.
American Cancer Society. Hormone Therapy for Breast Cancer. Atlanta: American
Cancer Society; 2016. http://www.cancer.org/cancer/breastcancer/detailedguide/
breast-cancer-treating-hormone-therapy.
American Cancer Society. Radiation Therapy for Breast Cancer. Atlanta: American
Cancer Society; 2016. http://www.cancer.org/cancer/breastcancer/detailedguide/
breast-cancer-treating-radiation.
American Cancer Society. Targeted Therapy for Breast Cancer. Atlanta: American
Cancer Society; 2016. http://www.cancer.org/cancer/breastcancer/detailedguide/
breast-cancer-treating-targeted-therapy.

72

Arroyo, J. & López, M. Psychological Problems Derived from Mastectomy: A
Qualitative Study. International Journal of Surgical Oncology, 2011, 2011,
132461-132470.
Babili, F., Bouajila, J., Fouraste, I., Valentin, A., Mauret, S., & Moulis, C. Chemical
study, antimalarial and antioxidant activities, and cytotoxicity to human breast
cancer cells (MCF7) of Argania spinosa. Phytomedicine: International Journal of
Phytotherapy & Phytopharmacology, 2010, 17(2), 157-160.
Banerjee, N., Talcott, S., Safe, S., & Mertens-Talcott, S. Cytotoxicity of Pomegranate
Polyphenolics in Breast Cancer Cells in Vitro and Vivo - Potential Role of
miRNA-27a and miRNA-155 in Cell Survival and Inflammation. Breast Cancer
Research and Treatment, 2012, 136(1), 21–34.
Barcellos-Hoff, M., Aggeler, J., Ram, T., & Bissell, M. Functional differentiation and
alveolar morphogenesis of primary mammary cultures on reconstituted basement
membrane. Development, 1989, 105(2), 223-235.
Basta, P., Bak, A., & Roszkowski, K. Cancer Treatment in Pregnant Women.
Contemporary Oncology, 2015, 19(5), 354–360.
Bawadi, H., Bansode, R., Trappey, A., Truax, R., & Losso, J. Inhibition of Caco-2
Colon, MCF-7 and Hs578T Breast, and DU 145 Prostatic Cancer Cell
Proliferation by Water-soluble Black Bean Condensed Tannins. Cancer Letters,
2005, 218(2), 153-162.

73

Bland, K. & Copeland, E. The breast: comprehensive management of benign and
malignant diseases. W.B. Saunders, Philadelphia, 1998.
Bodai, B. & Tuso, P. Breast Cancer Survivorship: A Comprehensive Review of LongTerm Medical Issues and Lifestyle Recommendations. The Permanente Journal,
2015, 19(2), 48–79.
Booth, B., Inskeep, B., Shah, H., Park, J., Hay, E., & Burg, K. Tannic Acid
Preferentially Targets Estrogen Receptor-Positive Breast Cancer. International
Journal of Breast Cancer, 2013, 1-9.
Braicu, C., Gherman, C., Irimie, A., & Berindan-Neagoe, I. Epigallocatechin-3-Gallate
(EGCG) Inhibits Cell Proliferation and Migratory Behaviour of Triple Negative
Breast Cancer Cells. Journal of Nanoscience and Nanotechnology, 2013, 13(1),
632-637.
Carlsen, M., Halvorsen, B., Holte, K., Bohn, S., Dragland, S., Sampson, L., Willey, C.,
Senoo, H., Umezono, Y., Sanada, C., Barikmo, I., Berhe, N., Willett, W., Phillips,
K., Jacobs, D., & Blomhoff, R. The Total Antioxidant Content of More than 3100
Foods, Beverages, Spices, Herbs and Supplements Used Worldwide. Nutrition
Journal, 2010, 9(3).
Chau, A., Jafarian, N., & Rosa, M. Male Breast: Clinical and Imaging Evaluations of
Benign and Malignant Entities with Histologic Correlation. The American Journal
of Medicine, 2016, 129(8), 776-791.

74

Chung, K., Wong, T., Wei, C., Huang, Y., & Lin, Y. Tannins and Human Health: A
Review. Critical Reviews in Food Science and Nutrition, 1998, 38(6), 421-464.
Eddy, S., Kane, S., & Sonenshein, G. Trastuzumab-Resistant HER2-Driven Breast
Cancer Cells Are Sensitive to Epigallocatechin-3 Gallate. Cancer Research, 2007,
67(19), 9018-9023.
Foster, F., Owens, T., Tanianis-Hughes, J., Clarke, R., Brennan, K., Bundred, N., &
Streuli, C. Targeting inhibitor of apoptosis proteins in combination with ErbB
antagonists in breast cancer. Breast Cancer Research, 2009, 11(3).
Fujita, E., Egashira, J., Urase, K., Kuida, K., & Momoi, T. Caspase-9 Processing by
Caspase-3 via a Feedback Amplification Loop in Vivo. Cell Death and
Differentiation, 2001, 8(4), 335-344.
Howlader, N., Altekruse, S., Li, C., Chen, V., Clarke, C., Ries, L., & Cronin, K. US
Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and
HER2 Status. Journal of the National Cancer Institute, 2014, 106(5).
Huang, H., Lin, C., & Lin, J. 1,2,3,4,6-Penta- O -galloyl-β- D -glucose, Quercetin,
Curcumin and Lycopene Induce Cell-Cycle Arrest in MDA-MB-231 and BT474
Cells through Downregulation of Skp2 Protein. Journal of Agricultural and Food
Chemistry, 2011, 59(12), 6765-6775.
Javed, A. & Lteif, A. Development of the Human Breast. Seminars in Plastic Surgery,
2013, 27(1), 5-12.

75

Kalogerakos, K., Sofoudis, C., Koumousidis, A., Tzonis, P., & Maniou, I. Breast cancer
surgery in the elderly women: A review. OA Women’s Health, 2014, 2(1).
Keck School of Medicine of USC. USC Breast Center: Lumpectomy. Los Angeles,
University of Southern California; 2016. http://www.surgery.usc.edu/uppergigeneral/breastcenter-surgery-lumpectomy.html.
Khan, N. & Mukhtar, H. Cancer and Metastasis: Prevention and Treatment by Green
Tea. Cancer and Metastasis Review, 2010, 29(3), 435–445.
Khanbabaee, K. & van Ree, T. Tannins: Classification and Definition. Natural Product
Reports, 2001, 18(6), 641-649.
Kim, N., Mehta, R., Yu, W., Neeman, I., Livney, T., Amichay, A., Poirier, D., Nicholls,
P., Kirby, A., Jiang, W., Mansel, R., Ramachandran, C., Rabi, T., Kaplan, B., &
Lansky, E. Chemopreventive and Adjuvant Therapeutic Potential of Pomegranate
(Punica Granatum) for Human Breast Cancer. Breast Cancer Research and
Treatment, 2002, 71(3), 203-217.
Kuhajda, F. Fatty-acid Synthase and Human Cancer: New Perspectives on Its Role in
Tumor Biology. Nutrition, 2000, 16(3), 202-208.
Li, M., Yin, Y., Wang, J., & Jiang, Y. Green Tea Compounds in Breast Cancer
Prevention and Treatment. World Journal of Clinical Oncology, 2014, 5(3), 520528.

76

Losso, J., Bansode, R., Trappey, A., Bawadi, H., & Truax, R. In Vitro Antiproliferative Activities of Ellagic Acid. The Journal of Nutritional Biochemistry,
2004, 15(11), 672-678.
Ma, J. & Jemal, A. Breast Cancer Metastasis and Drug Resistance. Springer, New
York, 2013, 1-18.
McKinley, M. & O’Loughlin, V. Human Anatomy, Third Edition. McGraw-Hill, New
York, 2012, 857-861.
Mocanu, M., Nagy, P., & Szöllősi, J. Chemoprevention of Breast Cancer by Dietary
Polyphenols. Molecules, 2015, 20(12), 22578-22620.
Mojzer, E., Hrnčič, M., Škerget, M., Knez, Z., & Bren, U. Polyphenols: Extraction
Methods, Antioxidative Action, Bioavailability and Anticarcinogenic Effects.
Molecules, 2016, 21(7).
Moongkarndi, P., Kosem, N., Kaslungka, S., Vallisuta, O., Pongpan, N., & Neungton,
N. Antiproliferation, Antioxidation and Induction of Apoptosis by Garcinia
Mangostana (mangosteen) on SKBR3 Human Breast Cancer Cell Line. Journal of
Ethnopharmacology, 2004, 90(1), 161-166.
Nakamoto, J. Myths and variations in normal pubertal development. Western Journal of
Medicine, 2000, 172(3), 182-185.

77

National Breast Cancer Foundation, Inc. Breast Cancer Stages. http://www.national
breastcancer.org/breast-cancer-stages.
National Breast Cancer Foundation, Inc. Stages 0 & 1. http://www.nationalbreastcancer
.org/breast-cancer-stage-0-and-stage-1.
National Breast Cancer Foundation, Inc. Stage 2. http://www.nationalbreastcancer
.org/breast-cancer-stage-2.
National Breast Cancer Foundation, Inc. Stage 3. http://www.nationalbreastcancer
.org/breast-cancer-stage-3.
National Breast Cancer Foundation, Inc. Stage 4. http://www.nationalbreastcancer
.org/breast-cancer-stage-4.
O’Connell, R. & Rusby, J. Anatomy relevant to conservative mastectomy. Gland
Surgery, 2015, 4(6), 476-483.
Oliveira, L., Carvalho, M., & Melo, L. Health Promoting and Sensory Properties of
Phenolic Compounds in Food. Revista Ceres, 2014, 6(1), 764-779.
Pandey, K. & Rizvi, S. Plant Polyphenols as Dietary Antioxidants in Human Health
and Disease. Oxidative Medicine and Cellular Longevity, 2009, 2(5), 270–278.
Peart, O. Breast Intervention and Breast Cancer Treatment Options. Radiologic
Technology, 2015, 86(5), 535-558.

78

Petridis, G. Tannins: Types, Foods Containing, And Nutrition. Nova Science Publishers
Inc., Hauppauge, 2011.
Santoro, N. & Randolph Jr., J. Reproductive Hormones and the Menopause Transition.
Obstetrics and gynecology clinics of North America, 2011, 38(3), 455-466.
Shirode, A., Kovvuru, P., Chittur, S., Henning, S., Heber, D., & Reliene, R.
Antiproliferative Effects of Pomegranate Extract in MCF-7 Breast Cancer Cells
Are Associated with Reduced DNA Repair Gene Expression and Induction of
Double Strand Breaks. Molecular Carcinogenesis, 2013, 53(6), 458-470.
Signoretti, S., Marcotullio, L., Richardson, A., Ramaswamy, S., Isaac, B., Rue, M.,
Monti, F., Loda, M., & Pagano, M. Oncogenic Role of the Ubiquitin Ligase
Subunit Skp2 in Human Breast Cancer. Journal of Clinical Investigation, 2002,
110(5), 633-641.
Sonoda, H., Inoue, H., Ogawa, K., Utsunomiya, T., Masuda, T., & Mori, M.
Significance of Skp2 Expression in Primary Breast Cancer. Clinical Cancer
Research, 2006, 12(4), 1215-1220.
Stich, H. & Rosin, M. Naturally occurring phenolics as antimutagenic and
anticarcinogenic agents. Nutritional and Toxicological Aspects of Food Safety,
1984, 177, 1-29.
Tikoo, K., Sane, M., & Gupta, C. Tannic Acid Ameliorates Doxorubicin-induced
Cardiotoxicity and Potentiates Its Anti-cancer Activity: Potential Role of Tannins

79

in Cancer Chemotherapy. Toxicology and Applied Pharmacology, 2010, 251(3),
191-200.
Vermerris, W. & Nicholson, R. Phenolic Compounds Biochemistry. Springer,
Dordrecht, 2006, 1–34.
Vernon, R., Gooden, M., Lara, S., & Wight, T. Microgrooved fibrillar collagen
membranes as scaffolds for cell support and alignment. Biomaterials, 2005, 26,
3131-3140.
Wakil, S. Fatty Acid Synthase, a Proficient Multifunctional Enzyme. Biochemistry,
1989, 28(11), 4523-4530.
Zand, R., Jenkins, D., & Diamandis, E. Steroid Hormone Activity of Flavonoids and
Related Compounds. Breast Cancer Research and Treatment, 2000, 62(1), 35-49.
Zhang, S., Zheng, C., Yan, X., & Tian, W. Low Concentration of Condensed Tannins
from Catechu Significantly Inhibits Fatty Acid Synthase and Growth of MCF-7
Cells. Biochemical and Biophysical Research Communications, 2008, 371(4),
654-658.
Zhu, W. & Nelson, C. Adipose and mammary epithelial tissue engineering. Biomatter,
2013, 3(3).
Zimmerman, M. & Mehr, S. Recurrence of Breast Cancer Years After the Initial
Tumor. The American Journal of Managed Care, 2014, 20(14), 19-24.

80

